- 专利标题： Neurodevelopmental disorder therapy
-
申请号： US16068703申请日： 2017-01-24
-
公开(公告)号： US10507196B2公开(公告)日： 2019-12-17
- 发明人: Christopher U. Missling
- 申请人： Anavex Life Sciences Corp.
- 申请人地址： US NY New York
- 专利权人： ANAVEX LIFE SCIENCES CORP.
- 当前专利权人： ANAVEX LIFE SCIENCES CORP.
- 当前专利权人地址： US NY New York
- 代理机构： Polsinelli PC
- 代理商 Tara A. Nealey
- 国际申请： PCT/US2017/014702 WO 20170124
- 国际公布： WO2017/132127 WO 20170803
- 主分类号： A61K31/341
- IPC分类号： A61K31/341 ; A61P25/00
摘要：
This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
公开/授权文献
- US20190022052A1 NEURODEVELOPMENTAL DISORDER THERAPY 公开/授权日：2019-01-24
信息查询
